The Board of Directors approved a one-for-ten (1:10) reverse stock split, which combined with the prior 1:10 split effective May 21, results in an aggregate one-for-one hundred (1:100) reduction. The transaction is expected to become effective at 12:01 a.m. ET on November 6, 2026, reducing outstanding shares from approximately 5.9 million to roughly 589,000. Fractional shares will be cashed out based on the closing price on November 5. Onconetix is a commercial-stage biotechnology company focused on oncology solutions and owns the Proclarix prostate cancer diagnostic test.
